One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Anthracyclines in Early Breast Cancer: The Long Goodbye
doi : 10.1200/JCO-24-01916
2025, Volume 43 (4)
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia
doi : 10.1200/JCO-24-01881
Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR -Mutated Non–Small Cell Lung Cancer: Old or New Regimen?
doi : 10.1200/JCO-24-01921
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial
doi : 10.1200/JCO.24.00836
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
doi : 10.1200/JCO.24.00975
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
doi : 10.1200/JCO.24.00533
Thoracic Radiotherapy Improves the Survival in Patients With EGFR -Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial
doi : 10.1200/JCO.23.02075
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2
doi : 10.1200/JCO.24.00176
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
doi : 10.1200/JCO.24.00640
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low
doi : 10.1200/JCO.23.02768
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
doi : 10.1200/JCO.24.00055
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)
doi : 10.1200/JCO.24.00795
Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation
doi : 10.1200/JCO-24-01824
Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation
doi : 10.1200/JCO-24-02108
Erratum: Risk Stratification in Older Intensively Treated Patients With AML
doi : 10.1200/JCO-24-02661
Erratum: A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease
doi : 10.1200/JCO-24-02716
